The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease
A pre-existing tumor-induced pro-inflammatory state significantly impacts COVID-19 outcomes in patients with cancer. The FLARE score, derived from circulating inflammatory markers, emerges as an easy-to-use, globally accessible, effective tool for clinicians to identify patients with cancer at heightened risk of severe COVID-19 complications and early mortality who might benefit most from immediate and intensive treatment strategies. Furthermore, our findings underscore the significance of immature neutrophils in the progression of COVID-19 in patients with cancer, advocating for further investigation into how these cells contribute to both cancer and COVID-19 disease.
Authors
- Marta García de Herreros (ORCID: https://orcid.org/0000-0001-8010-3584)
- Juan Manuel Torres (ORCID: https://orcid.org/0000-0002-7138-5732)
- Cristina Teixidó (ORCID: https://orcid.org/0000-0002-7226-6567)
- Laura Mezquita (ORCID: https://orcid.org/0000-0003-0936-7338)
- Xabier Mielgo-Rubio (ORCID: https://orcid.org/0000-0002-0985-6150)
- David Casadevall (ORCID: https://orcid.org/0000-0002-3986-2084)
- Fara Brasó‐Maristany (ORCID: https://orcid.org/0000-0001-5440-9643)
- Sara Pilotto (ORCID: https://orcid.org/0000-0003-2229-4874)
- Javier Gavira (ORCID: https://orcid.org/0000-0001-6385-3519)
- Édouard Auclin (ORCID: https://orcid.org/0000-0001-7039-4840)
- M.V. Bluthgen (ORCID: https://orcid.org/0000-0001-5343-218X)
- José Carlos Tapia (ORCID: https://orcid.org/0000-0001-6545-8862)
- Hugo Arasanz (ORCID: https://orcid.org/0000-0001-6838-6702)
- Lorena Lupinacci
- Marta Rodríguez (ORCID: https://orcid.org/0000-0003-1935-0951)
- Gonzalo Recondo (ORCID: https://orcid.org/0000-0002-0127-1019)
- Juan Carlos Laguna (ORCID: https://orcid.org/0000-0002-2357-1186)
- Marco Tagliamento (ORCID: https://orcid.org/0000-0001-7461-023X)
- Cristina Urbano
- Teresa Gorría
- J.N. Minatta (ORCID: https://orcid.org/0000-0002-3531-1920)
- Aleix Prat (ORCID: https://orcid.org/0000-0003-2377-540X)
- Rafael López Castro (ORCID: https://orcid.org/0000-0003-4770-4710)
- Elia Seguí (ORCID: https://orcid.org/0000-0001-7770-9825)
- Nicolas Epaillard (ORCID: https://orcid.org/0000-0001-7543-491X)
- Alexandru Vlagea (ORCID: https://orcid.org/0000-0003-3169-4597)
- Azucena González
- Victor Bolaño
- Mar Diaz Pavon
- Sara Peiro Carmona
Institutions
- University of Verona (IT)
- Université Paris Cité (FR)
- Hospital de Sant Pau (ES)
- Hospital Italiano de Buenos Aires (AR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospital Universitario Fundación Alcorcón (ES)
- Hôpital Européen Georges-Pompidou (FR)
- Hospital General de Granollers (ES)
- Navarre Institute of Health Research (ES)
- Hospital Quirónsalud Barcelona (ES)
- Hospital Clínic de Barcelona (ES)
- Corporació Sanitària Parc Taulí (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Del Mar (ES)
- Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (AR)
- Hospital Alemán (AR)
- Oryzon Genomics (Spain) (ES)
- Ospedale Policlinico San Martino (IT)
- Hospital Clínico Universitario de Valladolid (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
- University of Genoa (IT)
Publication Details
- Journal
- Cancers
- Published
- 2024-08-26
- DOI
- https://doi.org/10.3390/cancers16172974
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Breast Cancer Research Foundation
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Gilead Sciences
- American Society of Clinical Oncology
- European Commission
- Daiichi-Sankyo
- European Society for Medical Oncology
- Sociedad Española de Oncología Médica
- Fundación Fero
- Instituto de Salud Carlos III